EGFR mutation has been demonstrated to correlate with an immunosuppressive TME in non-small-cell lung cancer (NSCLC), and EGFR tyrosine kinase inhibitors (TKIs) may modulate the immune response by regulating TME (14–20). This evidence concerns the gene EGFR and non-small cell lung carcinoma.